Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Common Equity (2016 - 2021)

Historic Common Equity for Phio Pharmaceuticals (PHIO) over the last 10 years, with Q3 2021 value amounting to $25.2 million.

  • Phio Pharmaceuticals' Common Equity rose 6337.28% to $25.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $25.2 million, marking a year-over-year increase of 6337.28%. This contributed to the annual value of $13.0 million for FY2020, which is 12646.14% up from last year.
  • Phio Pharmaceuticals' Common Equity amounted to $25.2 million in Q3 2021, which was up 6337.28% from $28.8 million recorded in Q2 2021.
  • In the past 5 years, Phio Pharmaceuticals' Common Equity registered a high of $31.4 million during Q1 2021, and its lowest value of $567000.0 during Q1 2018.
  • For the 5-year period, Phio Pharmaceuticals' Common Equity averaged around $11.4 million, with its median value being $9.7 million (2019).
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 9312.48% in 2018, then soared by 195679.01% in 2019.
  • Over the past 5 years, Phio Pharmaceuticals' Common Equity (Quarter) stood at $1.8 million in 2017, then skyrocketed by 640.75% to $13.6 million in 2018, then tumbled by 57.67% to $5.7 million in 2019, then skyrocketed by 126.46% to $13.0 million in 2020, then surged by 93.95% to $25.2 million in 2021.
  • Its last three reported values are $25.2 million in Q3 2021, $28.8 million for Q2 2021, and $31.4 million during Q1 2021.